Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Cardiff Oncology Q2 EPS $(0.17) Up From $(0.51) YoY

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share. This is a 66.67 percent increase over losses of $(0.51) per share from the same period last year.
byBill Haddad
August 5, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share. This is a 66.67 percent increase over losses of $(0.51) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

WHO, On Covaxin Approval, Tells Benzinga The Technical Advisory Group ‘met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine….

By Benzinga Newsdesk
October 26, 1:58 PM
WHO Says 'The [Technical Advisory Group] expects to receive these clarifications from the manufacturer by the end of this week, and aims to reconvene for the final risk-benefit assessment on Wednesday, 3

OCGN